# NIH Reporter #1P50CA310825-01

Developing Novel Combination Immunotherapeutics for Non–Muscle-Invasive Bladder Cancer

**Recipient:** SLOAN-KETTERING INST CAN RESEARCH

**Award Amount:** $514,639.00
**Ceiling:** $514,639.00

**Awarded:** September 17, 2026

**Identifier:** 1P50CA310825-01

National Cancer Institute funding supports research into combination immunotherapies for non–muscle-invasive bladder cancer, including investigation of the engineered anti-CD40 antibody 2141-V11 and its effects on dendritic cells and antitumor immunity.

### Description

The project aims to elucidate how dendritic cells mediate immune responses to CD40 agonism, BCG, and other immunotherapies, and to inform combination treatment strategies for non–muscle-invasive bladder cancer. The work includes studying dendritic-cell and CD8 T-cell responses, testing combination approaches in preclinical models, and evaluating 2141-V11 alone and in combinations in patients.

[View original record](https://reporter.nih.gov/search/J7l2tQ4hHkqRePwGq3m5kA/project-details/11335850)